Indivior Pharmaceuticals appoints Jack A. Khattar as CEO as four executives depart

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.

Indivior Pharmaceuticals (NASDAQ:INDV) shares rose 3% on its last day as a standalone company after completing a merger with Supernus Pharmaceuticals (NASDAQ:SUPN). The combined company, to be named Supernus, aims for $125M in annual cost synergies, with Indivior shareholders owning 56.5% of the new entity.

Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader · Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flex

Supernus, Inc. completed its merger with Indivior Pharmaceuticals, creating a diversified CNS biopharmaceutical company. The combined entity will trade on Nasdaq under 'SUPN' starting November 3, 2026. Indivior shareholders will receive a $1 billion cash dividend. The merger enhances financial flexibility and expands the product portfolio.